Surmodics (SRDX)
(Delayed Data from NSDQ)
$37.66 USD
+0.09 (0.24%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $37.66 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$37.66 USD
+0.09 (0.24%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $37.66 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth B Momentum B VGM
Zacks News
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View
by Zacks Equity Research
Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.
SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
by Zacks Equity Research
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 31.25% and 6.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat
by Zacks Equity Research
Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 60.00% and 6.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool
by Zacks Equity Research
Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.
HRC vs. SRDX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. SRDX: Which Stock Is the Better Value Option?
HRC vs. SRDX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. SRDX: Which Stock Is the Better Value Option?
Surmodics' (SRDX) Q3 Earnings, Revenues Fall Shy of Estimates
by Zacks Equity Research
Higher revenues from the IVD segment drives Surmodics' (SRDX) fiscal third-quarter top line.
SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of -54.55% and -0.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HRC vs. SRDX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRC vs. SRDX: Which Stock Is the Better Value Option?
Surmodics (SRDX) Boosts Portfolio With Vetex Medical Buyout
by Zacks Equity Research
Surmodics' (SRDX) buyout of Vetex Medical adds second FDA 510 (k) cleared device to its thrombectomy platform.
HRC vs. SRDX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. SRDX: Which Stock Is the Better Value Option?
EYE or SRDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EYE vs. SRDX: Which Stock Is the Better Value Option?